Daratumumab in high-risk MGUS and low-risk smoldering myeloma: results of the Phase II D-PRISM study
- Omar Nadeem
- Michelle P. Aranha
- Robert A. Redd
- Michael Koontz
- Jeffrey V. Matous
- Andrew J. Yee
- Jeffrey A. Zonder
- Andrew Kin
- Sophie Magidson
- Elizabeth D. Lightbody
- Ting Wu
- Floris Chabrun
- Jean-Baptiste Alberge
- Ankit K. Dutta
- Jacqueline Perry
- Ashlee Sturtevant
- Mahshid Rahmat
- Junko Tsuji
- Christine Davie
- Caroline Ricciardi
- Frances Arters
- Marjorie Marto
- Amy Bergeron
- Jacalyn Rosenblatt
- Elizabeth K. O’Donnell
- Tarek H. Mouhieddine
- Lorena Pantano
- Jacob P. Laubach
- Paul G. Richardson
- Gad Getz
- Lorenzo Trippa
- Romanos Sklavenitis-Pistofidis
- Irene M. Ghobrial
2026-04-08